Heart Outcomes Prevention Evaluation (hope) Study - Epidemiology

Relevant Publications

Relationship Between Social Support and Clinical Outcomes: An Evaluation of Participant-Nominated Treatment Supporters in the HOPE 4 Intervention.

Issue Release: 2024

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers are Associated with Improved Amputation Free Survival in Chronic Limb-Threatening Ischemia.

Issue Release: 2024

The Differential Impact of Medical Therapy and Lifestyle Modification on Cardiovascular Health and Risk of Adverse Cardiovascular Events: A Narrative Review.

Issue Release: 2024

Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.

Issue Release: 2021

Exploring New Models for Cardiovascular Risk Reduction: The Heart Outcomes Prevention and Evaluation 4 (HOPE 4) Canada Pilot Study.

Issue Release: 2020

A novel method for interpreting survival analysis data: description and test on three major clinical trials on cardiovascular prevention.

Issue Release: 2020

The cost implication of primary prevention in the HOPE 3 trial.

Issue Release: 2019

Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.

Issue Release: 2019

Highlights from Selected Cardiovascular Disease Prevention Studies Presented at the 2019 European Society of Cardiology Congress.

Issue Release: 2019

Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients.

Issue Release: 2019

Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study.

Issue Release: 2018

Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial.

Issue Release: 2018

Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People.

Issue Release: 2017

High-Quality Statin Trials Support the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines After the HOPE-3 Trial (Heart Outcomes Prevention Evaluation-3): MESA (The Multiethnic Study of Atherosclerosis).

Issue Release: 2017

Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?

Issue Release: 2016

Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment.

Issue Release: 2016

Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants\' Baseline Characteristics.

Issue Release: 2015

Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms.

Issue Release: 2015

Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials.

Issue Release: 2014

Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population.

Issue Release: 2012

What is Maternal Age?

What Skills Are Essential for Field Researchers?

Why is Temporal Ambiguity Important?

What are the challenges faced when implementing AI and ML in Epidemiology?

What Are the Limitations of Serological Studies?

How do researchers ensure data quality?

How Do Social Determinants Affect Veterans' Health?

How Do We Collect Data?

When Should Interventions Be Implemented?

How to Monitor Recruitment Progress?

Heart Outcomes Prevention Evaluation (hope) Study - Epidemiology

Relevant Publications

Partnered Content Networks

Relevant Topics